Leerink Swann restated their outperform rating on shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) in a report published on Thursday morning. The firm currently has a $36.00 target price on the specialty pharmaceutical company’s stock.
Several other equities research analysts have also recently issued reports on AMAG. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a strong sell rating to a hold rating in a research note on Tuesday, July 5th. Jefferies Group lowered their target price on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a buy rating on the stock in a research note on Wednesday, August 10th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $36.33.
AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 24.05 on Thursday. AMAG Pharmaceuticals has a 12-month low of $17.92 and a 12-month high of $42.49. The stock has a 50 day moving average of $24.05 and a 200-day moving average of $23.97. The company’s market capitalization is $821.40 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a negative net margin of 4.87% and a positive return on equity of 13.98%. The company had revenue of $127.40 million for the quarter, compared to analysts’ expectations of $128.52 million. During the same quarter in the previous year, the company posted $1.12 EPS. The firm’s quarterly revenue was up 46.7% on a year-over-year basis. Equities analysts expect that AMAG Pharmaceuticals will post $5.55 earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 3,615 shares during the period. Teacher Retirement System of Texas raised its stake in shares of AMAG Pharmaceuticals by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,864 shares of the specialty pharmaceutical company’s stock worth $116,000 after buying an additional 589 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of AMAG Pharmaceuticals by 1,666.7% in the third quarter. Nisa Investment Advisors LLC now owns 5,300 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 5,000 shares during the period. Mason Street Advisors LLC acquired a new stake in shares of AMAG Pharmaceuticals during the second quarter worth about $162,000. Finally, Societe Generale acquired a new stake in shares of AMAG Pharmaceuticals during the second quarter worth about $232,000.
AMAG Pharmaceuticals Company Profile